Market Cap 5.21B
Revenue (ttm) 107.94M
Net Income (ttm) -107.35M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -99.45%
Debt to Equity Ratio 0.00
Volume 431,314
Avg Vol 489,100
Day's Range N/A - N/A
Shares Out 57.82M
Stochastic %K 41%
Beta 0.31
Analysts Strong Sell
Price Target $113.23

Company Profile

Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; ARC-SparX programs in Phase 1...

Industry: Biotechnology
Sector: Healthcare
Phone: 240 327 0630
Address:
800 Bridge Parkway, Redwood City, United States
PrivateProfiteer
PrivateProfiteer Nov. 14 at 4:34 AM
$ACLX is currently trading at $87.42, showing a moderate bullish sentiment as indicated by an RSI of 55.29, which is neither overbought nor oversold. The price is above the 30-day moving average (MA30) of $87.08, suggesting a short-term upward trend. The 50-day moving average (MA50) at $83.23 further supports this bullish outlook, indicating solid support below the current price. Given the recent high of $94.07 and low of $67.0 over the past 60 days, there is potential for a breakout. A suggested entry point would be around $87.50, slightly above the last close to confirm upward momentum. A stop loss can be set at $83.00, just below the MA50, to manage risk. Targets can be set at $92.00 (near the recent high) and $94.00, allowing for potential gains while considering the ATR of 4.05 for volatility. Overall, the trade plan is bullish based on the current metrics. https://privateprofiteers.com
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 13 at 2:41 AM
$ACLX is currently trading at $90.23, showing a strong upward trend as indicated by its last close above the 30-day moving average (MA30) of $86.64 and the 50-day moving average (MA50) of $82.54. The RSI at 64.08 suggests that the stock is approaching overbought territory, which may indicate a potential pullback or consolidation period. However, the stock remains within a bullish range, with a 60-day high of $94.07 and a low of $67.00. For a trade plan, consider entering a long position at $90.50, slightly above the current price to confirm momentum. Set a stop loss at $86.00 to manage risk. Target 1 can be set at $94.00, near the recent high, while Target 2 can be set at $96.00, allowing for further upside potential. Monitor RSI closely for signs of weakening momentum. https://privateprofiteers.com
0 · Reply
justiceforb_85
justiceforb_85 Nov. 13 at 12:10 AM
$ACLX this should be good news for anito-cel... https://www.fiercepharma.com/pharma/jj-legend-withdraw-ash-abstract-assessing-carvykti-against-gilead-arcellxs-rival-car-t
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 12 at 2:17 AM
$ACLX is currently trading at $90.23, showing a strong upward trend as indicated by its last close above the 30-day moving average (MA30) of $86.64 and the 50-day moving average (MA50) of $82.54. The RSI at 64.08 suggests that the stock is approaching overbought territory, which may indicate a potential pullback or consolidation period. However, the stock remains within a bullish range, with a 60-day high of $94.07 and a low of $67.00. For a trade plan, consider entering a long position at $90.50, slightly above the current price to confirm momentum. Set a stop loss at $86.00 to manage risk. Target 1 can be set at $94.00, near the recent high, while Target 2 can be set at $96.00, allowing for further upside potential. Monitor RSI closely for signs of weakening momentum. https://privateprofiteers.com
0 · Reply
justiceforb_85
justiceforb_85 Nov. 5 at 2:33 AM
$ACLX started a position. Impressed by lack of neurotoxicity with anito-cel and think this will be the go-to for BCMA CAR-T.
0 · Reply
JarvisFlow
JarvisFlow Nov. 3 at 1:26 PM
Canaccord Genuity has adjusted their stance on Arcellx ( $ACLX ), setting the rating to Buy with a target price of 121 → 130.
0 · Reply
Quantumup
Quantumup Nov. 3 at 12:06 PM
Canaccord Genuity⬆️ $ACLX's PT $130 from $121/reit'd Buy after conducting a detailed analysis of factors limiting $LEGN/ $JNJ CARVYKTI CART launch in MM, which all suggest favorable launch conditions for Arcellx in '26—based on its analysis of US CARVYKTI revs, the first 4Qs of the CARVYKTI rev could have been about 2x higher, accounting for issues w/ Out Of Specification (OOS) product, slow manufacturing time/infrastructure limitations We maintain our BUY rating and raise our price target on Arcellx to $130, based on higher anito-cel US launch revenues. We expect iMMagine-1's to show similar/better efficacy, and better safety vs. Legend/JnJ's CARTITUDE-1. We expect the ASH update in early December to reiterate the best-in-class profile of anito-cel. We also anticipate Kite's [ $GILD ] collaboration to support a smooth commercial launch in 4Q26. Arcellx currently holds ~$538M cash to support the company into 2028 for key data readouts and anito cel launch without additional fundraising.
0 · Reply
JarvisFlow
JarvisFlow Oct. 16 at 1:52 PM
Stifel has adjusted their stance on Arcellx ( $ACLX ), setting the rating to Buy with a target price of 129.
0 · Reply
Quantumup
Quantumup Oct. 16 at 11:51 AM
Stifel resumed coverage of $ACLX at a Buy rating and a $129 PT $LEGN - $JNJ $GILD Stifel said in its note:
0 · Reply
JarvisFlow
JarvisFlow Oct. 9 at 1:11 PM
Cantor Fitzgerald updates rating for Arcellx ( $ACLX ) to Neutral, target set at 88.
0 · Reply
Latest News on ACLX
Arcellx Provides Third Quarter 2025 Financial Results

Nov 5, 2025, 4:00 PM EST - 8 days ago

Arcellx Provides Third Quarter 2025 Financial Results


Arcellx Impressive Safety Data Leaves Doubts

Mar 17, 2025, 11:27 AM EDT - 8 months ago

Arcellx Impressive Safety Data Leaves Doubts


Arcellx Provides First Quarter 2024 Financial Results

May 9, 2024, 4:00 PM EDT - 1 year ago

Arcellx Provides First Quarter 2024 Financial Results


Arcellx to Participate in Two Upcoming Investor Conferences

May 7, 2024, 4:00 PM EDT - 1 year ago

Arcellx to Participate in Two Upcoming Investor Conferences


Arcellx: Navigating The CAR T-Cell Revolution

Jan 30, 2024, 5:13 AM EST - 1 year ago

Arcellx: Navigating The CAR T-Cell Revolution


Kite and Arcellx Announce Expansion in Strategic Partnership

Nov 15, 2023, 6:00 AM EST - 2 years ago

Kite and Arcellx Announce Expansion in Strategic Partnership

GILD


ARCELLX AND KITE ANNOUNCE EXPANSION IN STRATEGIC PARTNERSHIP

Nov 15, 2023, 6:00 AM EST - 2 years ago

ARCELLX AND KITE ANNOUNCE EXPANSION IN STRATEGIC PARTNERSHIP

GILD


Arcellx Provides First Quarter Financial Results

May 8, 2023, 4:00 PM EDT - 2 years ago

Arcellx Provides First Quarter Financial Results


Arcellx to Participate in Upcoming Investor Conferences

Feb 2, 2023, 4:00 PM EST - 3 years ago

Arcellx to Participate in Upcoming Investor Conferences


Arcellx: The Gilead Deal Derisks And Proves Their Technology

Jan 9, 2023, 12:46 PM EST - 3 years ago

Arcellx: The Gilead Deal Derisks And Proves Their Technology


PrivateProfiteer
PrivateProfiteer Nov. 14 at 4:34 AM
$ACLX is currently trading at $87.42, showing a moderate bullish sentiment as indicated by an RSI of 55.29, which is neither overbought nor oversold. The price is above the 30-day moving average (MA30) of $87.08, suggesting a short-term upward trend. The 50-day moving average (MA50) at $83.23 further supports this bullish outlook, indicating solid support below the current price. Given the recent high of $94.07 and low of $67.0 over the past 60 days, there is potential for a breakout. A suggested entry point would be around $87.50, slightly above the last close to confirm upward momentum. A stop loss can be set at $83.00, just below the MA50, to manage risk. Targets can be set at $92.00 (near the recent high) and $94.00, allowing for potential gains while considering the ATR of 4.05 for volatility. Overall, the trade plan is bullish based on the current metrics. https://privateprofiteers.com
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 13 at 2:41 AM
$ACLX is currently trading at $90.23, showing a strong upward trend as indicated by its last close above the 30-day moving average (MA30) of $86.64 and the 50-day moving average (MA50) of $82.54. The RSI at 64.08 suggests that the stock is approaching overbought territory, which may indicate a potential pullback or consolidation period. However, the stock remains within a bullish range, with a 60-day high of $94.07 and a low of $67.00. For a trade plan, consider entering a long position at $90.50, slightly above the current price to confirm momentum. Set a stop loss at $86.00 to manage risk. Target 1 can be set at $94.00, near the recent high, while Target 2 can be set at $96.00, allowing for further upside potential. Monitor RSI closely for signs of weakening momentum. https://privateprofiteers.com
0 · Reply
justiceforb_85
justiceforb_85 Nov. 13 at 12:10 AM
$ACLX this should be good news for anito-cel... https://www.fiercepharma.com/pharma/jj-legend-withdraw-ash-abstract-assessing-carvykti-against-gilead-arcellxs-rival-car-t
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 12 at 2:17 AM
$ACLX is currently trading at $90.23, showing a strong upward trend as indicated by its last close above the 30-day moving average (MA30) of $86.64 and the 50-day moving average (MA50) of $82.54. The RSI at 64.08 suggests that the stock is approaching overbought territory, which may indicate a potential pullback or consolidation period. However, the stock remains within a bullish range, with a 60-day high of $94.07 and a low of $67.00. For a trade plan, consider entering a long position at $90.50, slightly above the current price to confirm momentum. Set a stop loss at $86.00 to manage risk. Target 1 can be set at $94.00, near the recent high, while Target 2 can be set at $96.00, allowing for further upside potential. Monitor RSI closely for signs of weakening momentum. https://privateprofiteers.com
0 · Reply
justiceforb_85
justiceforb_85 Nov. 5 at 2:33 AM
$ACLX started a position. Impressed by lack of neurotoxicity with anito-cel and think this will be the go-to for BCMA CAR-T.
0 · Reply
JarvisFlow
JarvisFlow Nov. 3 at 1:26 PM
Canaccord Genuity has adjusted their stance on Arcellx ( $ACLX ), setting the rating to Buy with a target price of 121 → 130.
0 · Reply
Quantumup
Quantumup Nov. 3 at 12:06 PM
Canaccord Genuity⬆️ $ACLX's PT $130 from $121/reit'd Buy after conducting a detailed analysis of factors limiting $LEGN/ $JNJ CARVYKTI CART launch in MM, which all suggest favorable launch conditions for Arcellx in '26—based on its analysis of US CARVYKTI revs, the first 4Qs of the CARVYKTI rev could have been about 2x higher, accounting for issues w/ Out Of Specification (OOS) product, slow manufacturing time/infrastructure limitations We maintain our BUY rating and raise our price target on Arcellx to $130, based on higher anito-cel US launch revenues. We expect iMMagine-1's to show similar/better efficacy, and better safety vs. Legend/JnJ's CARTITUDE-1. We expect the ASH update in early December to reiterate the best-in-class profile of anito-cel. We also anticipate Kite's [ $GILD ] collaboration to support a smooth commercial launch in 4Q26. Arcellx currently holds ~$538M cash to support the company into 2028 for key data readouts and anito cel launch without additional fundraising.
0 · Reply
JarvisFlow
JarvisFlow Oct. 16 at 1:52 PM
Stifel has adjusted their stance on Arcellx ( $ACLX ), setting the rating to Buy with a target price of 129.
0 · Reply
Quantumup
Quantumup Oct. 16 at 11:51 AM
Stifel resumed coverage of $ACLX at a Buy rating and a $129 PT $LEGN - $JNJ $GILD Stifel said in its note:
0 · Reply
JarvisFlow
JarvisFlow Oct. 9 at 1:11 PM
Cantor Fitzgerald updates rating for Arcellx ( $ACLX ) to Neutral, target set at 88.
0 · Reply
dogDazeSummer
dogDazeSummer Sep. 20 at 9:12 PM
Wonder how ending the $11B US pharmaceutical advertising impacts small, medium and larger M&A targets. Immediate cash increase on balance sheets, especially biggest spender AbbVie’s Skyrzi. 20% of all US Television ads are Big Pharma. Would be interesting to see how this companies with Asia / Europe. Bigger issue is how it impacts long term revenue, how funds get reapproiated. https://www.wsj.com/business/media/trumps-crackdown-on-drug-ads-could-sting-tv-networks-673c322a?st=sdcBQq&reflink=article_copyURL_share $DAWN $IFRX $ACLX $VKTX $MLTX
4 · Reply
JarvisFlow
JarvisFlow Sep. 15 at 3:16 PM
Scotiabank has updated their rating for Arcellx ( $ACLX ) to Sector Outperform with a price target of 133.
0 · Reply
JarvisFlow
JarvisFlow Sep. 15 at 3:13 PM
B of A Securities updates rating for Arcellx ( $ACLX ) to Buy, target set at 80 → 84.
0 · Reply
NVDAMillionaire
NVDAMillionaire Sep. 4 at 8:55 AM
$ACLX Brilliant piece that captures ACLX's situation perfectly. So if you want to update your understanding of ACLX or get to know ACLX better, this is essential reading. https://beyondspx.com/quote/ACLX/arcellx-unlocking-cell-therapy-potential-with-d-domain-innovation-nasdaq-aclx#analysis
0 · Reply
PivotSkull
PivotSkull Aug. 23 at 4:36 AM
$ACLX Clinical stage immunology company with novel platform technology but pre-revenue and high cash burn
0 · Reply
Doozio
Doozio Aug. 17 at 10:34 PM
$ACLX it’s so nice let’s mention it twice! 🐒🍌🧠⏰♾️
0 · Reply
hbwalk2
hbwalk2 Aug. 15 at 11:21 PM
$ACLX Usually a good sign on a Friday. Not much option activity
0 · Reply
Doozio
Doozio Aug. 15 at 1:05 AM
$ACLX new baker bro pos? They about to become da 🧠 brothers wen XBI 🎉 s.
0 · Reply
Doozio
Doozio Aug. 14 at 7:51 PM
$ACLX out of the tightness after all da 🐑 been SPOT and da 🧠 is obviously spreading on the DLO while macro jabronis are calling for Thursday 🐑 corrections during 🐒🍌🧠⏰♾️
0 · Reply
hbwalk2
hbwalk2 Aug. 13 at 4:57 PM
$ACLX Head fake at open Someone in the know perhaps taking or adding to large position. $ANAB and $AXSM also looking strong
0 · Reply
Falcones
Falcones Aug. 13 at 4:57 PM
$ACLX Nice, who bought the dip today?
0 · Reply
d_risk
d_risk Aug. 8 at 12:49 PM
$ACLX - Arcellx Inc. Common Stock - 10Q - Updated Risk Factors ACLX’s latest 10-Q risk factors overhaul highlights new threats from clinical trial variability, manufacturing and regulatory hurdles, reliance on Kite and third parties, global IP and patent uncertainties, expanded compliance and anti-corruption risks, market adoption and reimbursement challenges, and warns of major stock volatility, dilution, and large Gilead share resales. #Biotechnology #MarketVolatility #IntellectualProperty #RegulatoryRisk #ClinicalTrials 🟢 Added 🟠 Removed https://d-risk.ai/ACLX/10-Q/2025-08-07
0 · Reply